Although a variety of molecular targets are being explored for NSCLCs, such as EGFR, ALK, MEK and KRAS, etc. [4,5], which offer a means for the development of drugs to combat tumors through genetic and epigenetic cues, effective treatments for lung cancer without known specific targeting molecules remain elusive. This evidence concerns the gene EGFR and lung carcinoma.